TXG · NASDAQ · STOCK
10x Genomics (TXG) Stock Analysis
$70.58
52W $11.62 – $102.81
57/100
$9.11B
-121.7
1.99
Is TXG Bullish or Bearish?
Bullish.
Innellis AI committee rates 10x Genomics, Inc. (TXG) Buy with a composite score of 57/100
, based on 6 analysts with 50% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +17.51 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -2.49 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.27 across 20 articles, 14d). Portfolio Manager remains cautious — 2 existing position pair(s) are highly correlated already. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 35.8% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 51%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -9.3% -- cheap may mean cheap for a reason
Growth Analyst
neutral
43
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− Revenue declining -4.3% YoY -- this is not a growth story right now
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 35.8% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 20 articles, 14d)
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 60.3 to 57.5.
- New bearish signals: 1 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: score 30->35 (+5).
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
38.0
Neutral
MACD Histogram
-2.612
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.19
Inside Bands
Price vs Moving Averages
EMA 9
$78.18
Below
EMA 21
$78.44
Below
EMA 50
$70.23
Above
EMA 200
$44.04
Above
Fundamental Analysis
Valuation
67
Growth
56
Profitability
25
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
-121.7×
P/B Ratio
11.30×
PEG Ratio
0.27
Dividend Yield
0.00%
52W High
$102.81
52W Low
$11.62
Quality & Growth
ROE
-546.8%
ROA
-418.1%
Gross Margin
7003.1%
Operating Margin
-1432.7%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
P/E ratio of -121.7 (inexpensive relative to a 15-40x range); Price-to-book of 11.3x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -5.5%; Return on assets of -4.2%; Net margin of -12.2%; Gross margin of 70.0%; Current ratio of 5.69 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow per share is positive (0.93); Most recent quarter beat estimates by 43.1%; 4 consecutive earnings beats; EPS growth decelerating (+23.1% -> -40.0% QoQ); Analyst estimates falling over recent quarters
Get the Full TXG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →